Skip to main content
Erschienen in: Familial Cancer 3/2014

01.09.2014 | Original Article

Evaluating the utilization of educational materials in communicating about Lynch syndrome to at-risk relatives

verfasst von: Kristen Dilzell, Kerry Kingham, Kelly Ormond, Uri Ladabaum

Erschienen in: Familial Cancer | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Facilitating family communication about Lynch syndrome is a public health priority since following appropriate screening guidelines can decrease morbidity and mortality. The aims of this study were to (1) ascertain what educational materials individuals with Lynch syndrome provide to at-risk relatives, and (2) identify relationships between receiving educational materials and pursuing clinical follow-up. Seventy-four participants, recruited from the Stanford Cancer Institute and a support group, completed an online questionnaire; 50 were first to be diagnosed with a Lynch syndrome mutation in their family (probands) and 24 were first or second-degree relatives. Probands reported informing 88 % (184/209) of first-degree relatives and 64 % (161/252) of second-degree relatives of the mutation. Probands shared their genetic counseling note with 53 % of relatives; other resources, including family letters, personal notes, testing laboratory information, online resources, support group information, and genetics referrals, were given to 33 % or fewer relatives. Probands reported that female relatives (p = 0.028) and first-degree relatives (p ≤ 0.001) were more likely to be given materials. Relatives who received an educational material were more likely to follow up with a clinician (74 vs 22 %, p ≤0.001) and attend a genetic counseling appointment (43 vs 16 %, p ≤ 0.001). First-degree relatives who received an educational material were more likely to have undergone genetic testing (51 vs 19 %, p = 0.012) and cancer screening (69 vs 29 %, p = 0.001). Facilitating information transmission in families with Lynch syndrome using educational materials may play a role in informed clinical decision-making and cascade screening of at-risk relatives.
Literatur
1.
Zurück zum Zitat Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal V.1.2014. © National Comprehensive Cancer Network, Inc 2014. All rights reserved. Accessed 22 April 2014. (To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc) Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal V.1.2014. © National Comprehensive Cancer Network, Inc 2014.  All rights reserved.  Accessed 22 April 2014.  (To view the most recent and complete version of the guideline, go online to www.​nccn.​org.  NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc)
3.
Zurück zum Zitat Recommendations from the EGAPP Working Group (2009) Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11(1):35–41. doi:10.1097/GIM.0b013e31818fa2ff CrossRef Recommendations from the EGAPP Working Group (2009) Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11(1):35–41. doi:10.​1097/​GIM.​0b013e31818fa2ff​ CrossRef
8.
Zurück zum Zitat Dugan R, Wiesner G, Juengst E, O’Riordan M, Matthews A, Robin N (2003) Duty to warn at-risk relatives for genetic disease: genetic counselors’ clinical experience. Am J Med Genet C Semin Med Genet 119C(1):27–34. doi:10.1002/ajmg.c.10005 PubMedCrossRef Dugan R, Wiesner G, Juengst E, O’Riordan M, Matthews A, Robin N (2003) Duty to warn at-risk relatives for genetic disease: genetic counselors’ clinical experience. Am J Med Genet C Semin Med Genet 119C(1):27–34. doi:10.​1002/​ajmg.​c.​10005 PubMedCrossRef
9.
Zurück zum Zitat Pate v. Threlkel, 661 So.2d 278 (Fla. 1995) Pate v. Threlkel, 661 So.2d 278 (Fla. 1995)
10.
Zurück zum Zitat Safer v. Estate of Pack, 677 A.2d (N.J. Super. Ct. App’ Div. 1996) Safer v. Estate of Pack, 677 A.2d (N.J. Super. Ct. App’ Div. 1996)
11.
Zurück zum Zitat Molloy v. Meier. 679 NW.2d 711 (Minn. 2004) Molloy v. Meier. 679 NW.2d 711 (Minn. 2004)
12.
Zurück zum Zitat Vos J, Menko F, Jansen A, van Asperen C, Stiggelbout A, Tibben A (2011) A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer 10(1):87–96. doi:10.1007/s10689-010-9385-y PubMedCentralPubMedCrossRef Vos J, Menko F, Jansen A, van Asperen C, Stiggelbout A, Tibben A (2011) A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer 10(1):87–96. doi:10.​1007/​s10689-010-9385-y PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Aktan-Collan KI, Kaariainen HA, Kolttola EM, Pylvanainen K, Jarvinen HJ, Haukkala AH, Mecklin JP (2011) Sharing genetic risk with next generation: mutation-positive parents’ communication with their offspring in Lynch syndrome. Fam Cancer 10(1):43–50. doi:10.1007/s10689-010-9386-x PubMedCrossRef Aktan-Collan KI, Kaariainen HA, Kolttola EM, Pylvanainen K, Jarvinen HJ, Haukkala AH, Mecklin JP (2011) Sharing genetic risk with next generation: mutation-positive parents’ communication with their offspring in Lynch syndrome. Fam Cancer 10(1):43–50. doi:10.​1007/​s10689-010-9386-x PubMedCrossRef
16.
Zurück zum Zitat Sharaf RN, Myer P, Stave CD, Diamond LC, Ladabaum U (2013) Uptake of genetic testing by relatives of Lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol 11(9):1093–1100. doi:10.1016/j.cgh.2013.04.044 Sharaf RN, Myer P, Stave CD, Diamond LC, Ladabaum U (2013) Uptake of genetic testing by relatives of Lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol 11(9):1093–1100. doi:10.​1016/​j.​cgh.​2013.​04.​044
19.
Zurück zum Zitat Menko FH, Aalfs CM, Henneman L, Stol Y, Wijdenes M, Otten E et al (2013) Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticists. Fam Cancer 12(2):319–324. doi:10.1007/s10689-013-9636-9 Menko FH, Aalfs CM, Henneman L, Stol Y, Wijdenes M, Otten E et al (2013) Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticists. Fam Cancer 12(2):319–324. doi:10.​1007/​s10689-013-9636-9
20.
Zurück zum Zitat Forrest L, Delatycki M, Curnow L, Skene L, Aitken M (2010) Genetic health professionals and the communication of genetic information in families: practice during and after and genetic consultation. Am J Med Genet A 152A:1458–1466. doi:10.1002/ajmg.a.33385 Forrest L, Delatycki M, Curnow L, Skene L, Aitken M (2010) Genetic health professionals and the communication of genetic information in families: practice during and after and genetic consultation. Am J Med Genet A 152A:1458–1466. doi:10.​1002/​ajmg.​a.​33385
21.
Zurück zum Zitat Mesters I, Ausems M, Eichhorn S, Vasen H (2005) Informing one’s family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer 4(2):163–167. doi:10.1007/s10689-004-7992-1 PubMedCrossRef Mesters I, Ausems M, Eichhorn S, Vasen H (2005) Informing one’s family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer 4(2):163–167. doi:10.​1007/​s10689-004-7992-1 PubMedCrossRef
23.
Zurück zum Zitat Chivers Seymour K, Addington-Hall J, Lucassen AM, Foster CL (2010) What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns 19(4):330–342. doi:10.1007/s10897-010-9296-y PubMedCrossRef Chivers Seymour K, Addington-Hall J, Lucassen AM, Foster CL (2010) What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns 19(4):330–342. doi:10.​1007/​s10897-010-9296-y PubMedCrossRef
24.
Zurück zum Zitat McCann S, MacAuley D, Barnett Y, Bunting B, Bradley A, Jeffers L, Morrison PJ (2009) Family communication, genetic testing and colonoscopy screening in hereditary non-polyposis colon cancer: a qualitative study. Psychooncology 18(11):1208–1215. doi:10.1002/pon.1487 PubMedCrossRef McCann S, MacAuley D, Barnett Y, Bunting B, Bradley A, Jeffers L, Morrison PJ (2009) Family communication, genetic testing and colonoscopy screening in hereditary non-polyposis colon cancer: a qualitative study. Psychooncology 18(11):1208–1215. doi:10.​1002/​pon.​1487 PubMedCrossRef
25.
26.
Zurück zum Zitat Wakefield CE, Meiser B, Homewood J, Ward R, O’Donnell S, Kirk J (2008) Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk. Cancer 113(5):956–965. doi:10.1002/cncr.23681 PubMedCrossRef Wakefield CE, Meiser B, Homewood J, Ward R, O’Donnell S, Kirk J (2008) Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk. Cancer 113(5):956–965. doi:10.​1002/​cncr.​23681 PubMedCrossRef
28.
Zurück zum Zitat Peterson S, Watts B, Koehly L, Vernon S, Balie W, Kohlmann W, Gritz, E (2003) How families communicate about HNPCC genetic testing: findings from a qualitiave study. Am J Med Genet C 119C:78–86. Peterson S, Watts B, Koehly L, Vernon S, Balie W, Kohlmann W, Gritz, E (2003) How families communicate about HNPCC genetic testing: findings from a qualitiave study. Am J Med Genet C 119C:78–86.
Metadaten
Titel
Evaluating the utilization of educational materials in communicating about Lynch syndrome to at-risk relatives
verfasst von
Kristen Dilzell
Kerry Kingham
Kelly Ormond
Uri Ladabaum
Publikationsdatum
01.09.2014
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 3/2014
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9720-9

Weitere Artikel der Ausgabe 3/2014

Familial Cancer 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.